Zagotenemab (Anti-Tau)

Synonyms: LY33003560

Catalog No.A2341 Purity:99%

Zagotenemab (Anti-Tau) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. It has the potential to be used in Alzheimer's disease research. MW : 145.5 KD

Purity & Quality Control

Batch: A234101 Purity: 99% Protein concentration: 11.36mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective Microtubule Associated Inhibitors

Name	Citation	Microtubule Associated	Microtubule Associated
Patupilone (Epothilone B)	16	+++
Plinabulin	5	++++
Lexibulin (CYT997)	8	++++
Epothilone A	5	++
CW069	7	+
RMC-4630	0		+++
Parbendazole	0	++
Combretastatin A4	5	+++
CK-636	4	+
ABT-751 (E7010)	✔
Nocodazole	✔		Abl,Abl (E255K),Abl (T315I)
T-1101 tosylate	✔
iHAP1	✔
Trigonelline	✔		Akt,PI3K,PLCγ1
Myoseverin	✔
Indibulin	✔
EGFR Inhibitor	✔		EGFR
MMAF	✔
DM1 (Mertansine)	✔
SSE15206	✔
ELR-510444	✔
TAI-1	✔
INH6	✔
INH1	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Zagotenemab (Anti-Tau) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. It has the potential to be used in Alzheimer's disease research. MW : 145.5 KD

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2019133-28-7
Molecular Weight	145.5 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.